V Vm Test Records
Muredac Ford
MyVirginiaMason is your tool to access portions of your health records 24 hours a day, seven days a week. It is also a convenient way to stay in touch with your care team. MyVirginiaMason is available on your desktop, tablet, or smartphone.
We also offer the ability for you to securely connect your health records to some of the Apple Health, MyVirginiaMason, and health management apps you may use (i.e. fitness trackers, dietary trackers, etc.). Android and other devices are not yet supported.
Virginia Mason's MyVirginiaMason patient portal allows you to go online to request appointments, schedule select appointments yourself, view lab results, send secure messages to your care teams, request prescription renewals, and see a summary of medications, allergies, immunizations, and medical issues.
Enrolling in MyVirginiaMason will take less than five minutes, and your provider's office will have much of the information needed. You will need to have proper identification with you to enroll. Acceptable forms of ID include:
Most lab test results are viewable in MyVirginiaMason. Radiology and pathology reports are viewable four calendar days (96 hours) after they are final (not four calendar days after the exam). Currently microbiology lab results are not available in MyVirginiaMason.
Our frontline teams will make every effort to review your message and direct them to appropriate care provider teams within 1 business day. Your clinical team will address your concerns in 3-5 business days. Secure portal messages are not intended to be used for medical emergencies.
To complement in-person and video appointments, we are pleased to offer you appointments through MyVirginiaMason. When appropriate and with your consent, our clinicians are happy to address your concerns by MyVirginiaMason message.
No. For security reasons, you should not send confidential information via email. If you choose to communicate with your care team, you will need to use secure messages through MyVirginiaMason. To complement in-person and video appointments, we are pleased to offer you appointments through MyVirginiaMason. When appropriate and with your consent, our clinicians are happy to address your concerns by MyVirginiaMason message.
Yes. Most clinical notes are available in MyVirginiaMason starting July 1, 2014. Clinical notes from July 1 forward are viewable in the patient portal, but notes before that date are not viewable. Clinical notes from before July 1 can be requested through Virginia Mason's Health Information Services Department (Medical Records).
Health information for minors 13-17 years old is specially protected by Washington State statutes and the federal HIPAA privacy rule. We do not offer MyVirginiaMason accounts to minors in this age group or parental access accounts for the parents/guardians of these minors.
We are currently in the process of doing several Domain Controller upgrades. Before I started here a previous Admin had started the process of moving our DCs from 2008 R2 Standard to 2008 R2 Enterprise. There was a PDC, DC2008S-0, and one additional DC, DC2008E-1 running. There was a 3rd 2008 Enterprise DC that was sitting on a VM that was shutdown. ALL of this was a leftover project from upgrading the DCs from 2003. The previous admin felt that Standard was not enough for the DCs and that those licenses were purchased in error, so after floating two standard DCs the enterprise DC was added and a standard DC was demoted.
The Enterprise DC was not replicating SYSVOL at all. The MSDCS zone was missing on the Enterprise DC as well. There was also some meta-data cleanup that had to occur for the fully tombstoned DC (the spare 2008E that was sitting on a shutdown VM). After quite a bit of troubleshooting we did an authoritative restore from the PDC. Afterwards SYSVOL appeared to be replicating properly, we added MSDCS manually and all the records pulled in. This was probably 8 or 9 months ago. Everything has been working smoothly since; logins, gpo replication, new gpos, new AD accounts - as well as a Hybrid migration to O365, and all the AD sync and Dir sync stuff worked great as well.
Update the functional level of the Domain and Forest from 2003 to 2008 (this included migrating from FRS to DFRS)Nuke the shutdown 2nd Enterprise DC, reinstall it, give it a DC role and add it to the domain.Move FSMO roles, etc to the first Enterprise DC and make it the PDC.Decommission the Standard DC.
This is our only failure when checking DC health with DCDIAG against each DC. When running the gui AD Replication Status Tool v1.0 as well as two PS scripts from TechNET, the AD and SYSVOL Replication/Latency Convergence Checks.
I'm not sure if this is best way to express that I can find the records manually, but I ran NSLOOKUP against all three DCs for one of the records listed above and it appears that it is found on all three.
It would appear that I had overlooked some output from the full DCDIAG set of tests I was running. There are some more specific errors being reported. And there's also much more granularity when it comes to how the DNS SRV records are being reported.
Copyright: 2015 Raben et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Funding: The HIDES study was funded by the HIV in Europe initiative which has received funding from Gilead Sciences, Merck, Tibotec, Pfizer, Schering-Plough,Abbott, BoehringerIngelheim, Bristol-Myers Squibb, GlaxoSmithKline, ViiVHealthcare. The operational procedures within the initiative include the following in order to maintain the autonomy of the initiative. The Steering Committee is the governing body and sponsors do not have representation on the Steering Committee. Furthermore, data, records, reports, Intellectual Property Rights and Know How generated as result of the initiative shall be deemed vested in and the property of the Steering Committee, represented by AIDS Fonds Netherlands and CHIP, Rigshospitalet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Late-stage diagnosis of HIV and undiagnosed HIV continue to be features of many European HIV epidemics [1]. Despite extensive work and the widespread use of a consensus definition of late presentation, 50% of patients newly diagnosed with HIV have a CD4 count
The present follow-up study, HIDES II, is expanding this testing strategy by increasing the number of indicator conditions and centres involved to identify those ICs with an HIV prevalence of >0.1%, [8, 9], and to ascertain whether there is variation in prevalence across Europe.
Six HIV indicator conditions were selected for auditing of HIV testing: tuberculosis (TB), hepatitis B and C (HEP), non-Hodgkin lymphoma (NHL), anal and cervical cancer (ACCAN) and oesophageal candidiasis (ECAN). These conditions fall into the category of AIDS defining conditions and/or conditions where the need for an HIV test is already widely accepted and should be part of clinical practice according to European and national HIV testing guidelines [10,11].
A call for collaboration was sent to healthcare centres/hospitals across the four regions of Europe: North, East, South and West [12]. Centres were eligible for participation if they routinely saw patients with one or more of the six ICs and were selected based on an aim of delivering a balanced number of audits per IC and regionally within the study.
Data was collected retrospectively from May 2013. Centers reviewed medical reports and submitted data electronically to the coordinating centre via an online CRF system (REDCap) [13]. The offer rate was defined as number offered an HIV test divided by the number of patients seen with unknown HIV status. The uptake rate was defined as the number tested for HIV divided by the number offered a test. The test rate was defined as the number tested divided by the number of patients seen with unknown HIV status and the HIV+ rate was defined as the number testing HIV+ divided by the number of patients seen with unknown HIV status. A high test rate was defined as a test rate above the median of 72% and a high offer rate as a offer rate above the median of 86%.
All rates were standardised for duration of the audit and number of patients seen within a calendar year. Data are reported as medians and interquartile ranges (IQR) across rates, as individual patient data was not available.
ICs were combined to non-malignant AIDS (TB and oesophageal candidiasis), malignant (NHL, anal and cervical cancer) and hepatitis to allow comparison across ICs. Regions were defined according to regions defined in EuroSIDA [12].
As centres were not independent (i.e. more than one audit originated from a number of centres), generalised estimating equations with a binomial distribution was used to determine odds of outcomes, using robust standard errors to account for repeated audits within centres. Two primary outcomes were investigated: the odds of having a high test rate, defined as greater than the median test rate across all audits, and a high testing positive rate, defined as >0.1% testing positive, the cut-off used to determine economic viability [7,8].
As an additional exercise, observed HIV positivity rates were applied for each region and IC to estimate the number of HIV diagnoses potentially missed. The HIV+ rate and 95% confidence interval was applied within each region and IC to all patients seen over the relevant time period to estimate the number of HIV positive diagnoses potentially missed, using the point estimate and the lower and upper limit of the confidence limit of the HIV rate among those actually tested.
c80f0f1006